From Seed to Sale: What VC's Want in Biotech Startups

Dr. Andrew Snyder (Monash University) joins the show to discuss the current biotech landscape: rising M&A and IPO activity, where clinical-stage assets are attracting buyers, and which therapeutic areas are gaining momentum (oncology, rare disease, metabolic/diabetes). He explains how AI is being deployed to speed research and data synthesis, the potential impact on drug development timelines, and why early-stage funding needs to return to replenish pipelines. They also touch on psychedelics research, recent breakthrough drugs affecting patient access, and the broader implications of drug-pricing policies on the industry. Practical advice for founders: tell a differentiated story, show a clear path to clinic, and demonstrate how quickly you can get safe patient data.

Timestamps: 0:00 Intro
0:20 Biotech market pulse: M&A, IPOs, XBI performance
2:10 Hot areas: clinical-stage assets, oncology, rare disease, metabolic disease
4:00 AI in biotech: speed, data synthesis, and limitations
6:05 Psychedelics & research policy
7:30 Drug pricing and broader policy considerations
8:30 Early-stage funding gap and advice for founders
10:10 Closing

Subscribe for more conversations with industry leaders and biotech analysis.
#tags
#Biotech #Pharma #DrugDevelopment #AIinBiotech #Oncology #RareDisease #ClinicalTrials #VentureCapital #StartupAdvice #BiotechNews

Видео From Seed to Sale: What VC's Want in Biotech Startups канала FinStreamTV